This Indian Firm Is Making 100 Crore Coronavirus Vaccines; 7 Indian Firms In The Vaccine Race!
The Coronavirus pandemic has managed to terrorize the entire world in no time. With innumerable deaths across the world, the pandemic has made it difficult for us to get out of our homes.
India is the third most affected country in the world now.
But here’s a silver lining – The Serum Institute of India, an Indian firm, is now working on making 100 crore coronavirus vaccines, and there are 7 more firms in line to be next!
Read on to find out all the details!
Serum Institute of India To Manufacture And Supply 100 Crore Doses of Vaccine For COVID-19
The Serum Institute of India has announced that the human trials for the AstraZeneca Oxford Vaccine will begin in India from August. The prestigious Oxford University has joined hands with AstraZeneca to develop a vaccine on the China-originated COVID-19 disease, and the Serum Institute has now partnered with the company to manufacture and distribute 1 billion doses of the vaccine.
Serum Institute of India CEO Adar Poonawalla confirmed the news, saying, “At present, we are working on the AstraZeneca Oxford vaccine which is undergoing phase III clinical trials. In addition to this, we will also start human trials in India in August 2020.”
He also revealed that these vaccines will be for India and other countries with middle to low income (GAVI countries) across the world.
These 7 Firms Developing Coronavirus Vaccine In India
Along with this, there are 7 more Indian firms that are working on developing a vaccine for this dangerous disease:
Covaxin, Bharat Biotech: This company has developed and manufactured a vaccine in Hyderabad, the human trials of which have started last week. They have also received approval to conduct the clinical trial in two phases.
AstraZeneca, Serum Institute of India: As informed above, the human trials will begin in August 2020 and hopefully the vaccine will be available at the end of the year.
ZyCoV-D, Zydus Cadila: This company has started the clinical trials last week with the first human dosing, and is planning to finish in about 7 months.
Panacea Biotec: The vaccine by this company hasn’t been named yet, but the company is planning to manufacture more than500 million doses of Covid-19 candidate vaccine, of which, over 40 million will be available for supply next year. Panacea Biotech has collaborated with a firm in Ireland with US-based Refana Inc, and set up a joint venture.
Indian Immunologicals vaccine: This is a subsidiary of the National Dairy Development Board. The Indian Immunologicals has entered into an agreement with Australia’s Griffith University to work towards developing a vaccine for the COVID-19 disease.
Mynvax: This company is developing a vaccine candidate that will probably be ready in 18 months, and will initially start with two dozen doses. They have also petitioned Biotechnology Industry Research Assistance Council (BIRAC) for a grant of Rs. 15 crore and is currently at pre-clinical trial level.
Biological E: This company is also working on a vaccine that is at a preclinical trial level as of now.